- Home
- ADPT vs WGS Comparison
ADPT vs WGS Comparison
Compare ADPT & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADPT
- WGS
- Stock Information
- Founded
- ADPT 2009
- WGS 2017
- Country
- ADPT United States
- WGS United States
- Employees
- ADPT N/A
- WGS N/A
- Industry
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- WGS Retail: Computer Software & Peripheral Equipment
- Sector
- ADPT Health Care
- WGS Technology
- Exchange
- ADPT Nasdaq
- WGS Nasdaq
- Market Cap
- ADPT 2.0B
- WGS 2.4B
- IPO Year
- ADPT 2019
- WGS N/A
- Fundamental
- Price
- ADPT $15.53
- WGS $119.71
- Analyst Decision
- ADPT Strong Buy
- WGS Strong Buy
- Analyst Count
- ADPT 10
- WGS 7
- Target Price
- ADPT $13.60
- WGS $102.14
- AVG Volume (30 Days)
- ADPT 2.0M
- WGS 513.3K
- Earning Date
- ADPT 11-06-2025
- WGS 10-28-2025
- Dividend Yield
- ADPT N/A
- WGS N/A
- EPS Growth
- ADPT N/A
- WGS N/A
- EPS
- ADPT N/A
- WGS 0.05
- Revenue
- ADPT $205,216,000.00
- WGS $362,321,000.00
- Revenue This Year
- ADPT $32.63
- WGS $36.01
- Revenue Next Year
- ADPT $16.31
- WGS $19.01
- P/E Ratio
- ADPT N/A
- WGS $2,494.07
- Revenue Growth
- ADPT 21.60
- WGS 48.70
- 52 Week Low
- ADPT $4.27
- WGS $54.14
- 52 Week High
- ADPT $15.94
- WGS $136.00
- Technical
- Relative Strength Index (RSI)
- ADPT 66.13
- WGS 50.34
- Support Level
- ADPT $14.11
- WGS $104.49
- Resistance Level
- ADPT $15.26
- WGS $132.00
- Average True Range (ATR)
- ADPT 0.73
- WGS 6.99
- MACD
- ADPT 0.12
- WGS -0.01
- Stochastic Oscillator
- ADPT 87.90
- WGS 55.32
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
About WGS GeneDx Holdings Corp.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.